Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 3,462 Shares of Company Stock

Key Points

• Insider sale: Soleil Boughton sold 3,462 Hims & Hers Health shares for approximately $95,551 under a pre-arranged Rule 10b5-1 plan, reducing the position by 1.16% while retaining 293,886 shares.
• Stock and financial performance: HIMS rose 1.2% to $29.68, while the company’s latest quarter showed 38.2% year-over-year revenue growth to $753.2 million but an EPS loss of $0.37, missing estimates.
• Analyst outlook: Analysts maintain a consensus “Hold” rating with an average price target of $32.43; the company also faces securities-litigation allegations involving customer data and billing practices, which remain unproven.

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) insider Soleil Boughton sold 3,462 shares of the company's stock in a transaction on Wednesday, October 28th. The shares were sold at an average price of $27.60, for a total value of $95,551.20. Following the transaction, the insider directly owned 293,886 shares in the company, valued at $8,111,253.60. This trade represents a 1.16% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, October 14th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.06, for a total value of $100,576.66.
• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total value of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.86, for a total transaction of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total value of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.55, for a total transaction of $691,808.05.

Hims & Hers Health Trading Up 1.2%

Shares of Hims & Hers Health stock traded up $0.36 during trading on Thursday, hitting $29.68. The company's stock had a trading volume of 7,405,111 shares, compared to its average volume of 22,401,816. The stock has a market cap of $6.92 billion, a price-to-earnings ratio of -47.11 and a beta of 2.44. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $48.34. The company has a debt-to-equity ratio of 4.21, a current ratio of 0.93 and a quick ratio of 0.87. The stock has a 50-day moving average price of $29.15 and a two-hundred day moving average price of $27.11.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). The company had revenue of $753.21 million during the quarter, compared to the consensus estimate of $698.90 million. Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The company's revenue for the quarter was up 38.2% on a year-over-year basis. During the same period last year, the firm posted $0.17 earnings per share. Equities research analysts anticipate that Hims & Hers Health, Inc. will post -0.16 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Truist Financial increased their price objective on Hims & Hers Health from $27.00 to $32.00 and gave the stock a "hold" rating in a report on Monday, August 24th. TD Cowen lifted their price objective on Hims & Hers Health from $25.00 to $30.00 and gave the company a "hold" rating in a research report on Tuesday, August 11th. Bank of America lifted their target price on Hims & Hers Health from $30.00 to $32.00 and gave the stock a "neutral" rating in a report on Tuesday, August 11th. Zacks Research raised Hims & Hers Health from a "strong sell" rating to a "hold" rating in a research note on Monday, July 13th. Finally, Barclays dropped their target price on shares of Hims & Hers Health from $39.00 to $35.00 and set an "overweight" rating on the stock in a report on Friday, August 21st. Three research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average target price of $32.43.

Key Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The development could expand Hims & Hers’ treatment offerings and support demand for its compounded-care business, prompting a recent rally in the stock. Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses Enforcement Discretion to Open Peptide Compounding
• Positive Sentiment: Hims & Hers also moved higher alongside telehealth peers after Teladoc reported better-than-expected revenue and profit. The broader sector strength may have provided additional support, although the report was not specific to Hims & Hers. Teladoc Soars as Revenue and Profit Beat Estimates
• Neutral Sentiment: Multiple law firms are soliciting investors to serve as lead plaintiff in a securities class action, with a November 2, 2026 deadline. The case covers investors who purchased HIMS shares from August 4, 2025, through July 29, 2026. These announcements largely repeat previously reported litigation information rather than represent a new company filing. HIMS November 2 Lead Plaintiff Deadline
• Negative Sentiment: The lawsuit stems from allegations that Hims & Hers shared private customer information with advertising platforms and used deceptive billing practices. Attorneys also cite the FTC’s broader complaint and a prior stock decline. If substantiated, the claims could create legal costs, regulatory exposure and reputational damage. The allegations have not been proven. Hims & Hers Securities Class Action Alert

Institutional Trading of Hims & Hers Health

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its position in Hims & Hers Health by 194.4% during the 1st quarter. Bank of America Corp DE now owns 4,357,672 shares of the company's stock worth $90,465,000 after acquiring an additional 2,877,550 shares during the period. State of Michigan Retirement System raised its stake in shares of Hims & Hers Health by 13.7% in the first quarter. State of Michigan Retirement System now owns 2,338,600 shares of the company's stock valued at $48,549,000 after purchasing an additional 280,900 shares in the last quarter. Bank of New York Mellon Corp acquired a new stake in Hims & Hers Health during the second quarter valued at approximately $46,220,000. Bienville Capital Management LLC bought a new stake in Hims & Hers Health in the second quarter valued at $27,242,000. Finally, Principal Financial Group Inc. increased its position in shares of Hims & Hers Health by 97.3% during the 1st quarter. Principal Financial Group Inc. now owns 1,282,266 shares of the company's stock worth $26,620,000 after purchasing an additional 632,282 shares in the last quarter. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.